Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab

Current oncology

S. D. Saibil¹  H. Majeed²  L. Bonilla³ 

[1] Princess Margaret Cancer Centre;Princess Margaret Cancer Centre, University Health Network;University of Toronto, University HealthNetwork

关键词: Melanoma;    checkpoint blockade;    myocarditis;   

DOI  :  10.3747/co.26.4381

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Combination immune checkpoint blockade with concurrent administration of the anti-ctla4 antibody ipilimumab and the anti PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases. That combination has also been associated with increased toxicity, including rare immune-related adverse events. Here we describe a case of fatal steroid-refractory myocarditis and panmyositis associated with the use of this combination in a patient with metastatic melanoma. Correlative studies indicated increased levels of serum interleukin 6 in this patient at the onset of toxicity, suggesting a possible role for anti– interleukin 6 receptor antibodies in the treatment of subsequent cases of this rare, but fatal, toxicity.

【 授权许可】

Unknown